Cargando…

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy

SIMPLE SUMMARY: Although sarcopenia-related factors, including decreased skeletal muscle index (SMI), have been reported to affect therapeutic efficacy and the occurrence of adverse events in sorafenib or lenvatinib treatment for hepatocellular carcinoma (HCC), there is considerably less evidence re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oura, Kyoko, Morishita, Asahiro, Manabe, Takushi, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Mimura, Shima, Tani, Joji, Ono, Masafumi, Ogawa, Chikara, Moriya, Akio, Senoo, Tomonori, Tsutsui, Akemi, Nagano, Takuya, Takaguchi, Koichi, Himoto, Takashi, Masaki, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296928/ https://www.ncbi.nlm.nih.gov/pubmed/37370853 http://dx.doi.org/10.3390/cancers15123243

Ejemplares similares

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study
por: Tani, Joji, et al.
Publicado: (2021)

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study
por: Tani, Joji, et al.
Publicado: (2020)

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease
por: Manabe, Takushi, et al.
Publicado: (2023)

Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
por: Morishita, Asahiro, et al.
Publicado: (2021)

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
por: Manabe, Takushi, et al.
Publicado: (2022)

Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
por: Oura, Kyoko, et al.
Publicado: (2021)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022)

Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up
por: Tadokoro, Tomoko, et al.
Publicado: (2021)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C
por: Fujita, Koji, et al.
Publicado: (2019)

Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis
por: Shi, Tingting, et al.
Publicado: (2020)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

MicroRNA Interference in Hepatic Host-Pathogen Interactions
por: Morishita, Asahiro, et al.
Publicado: (2021)

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review
por: Morishita, Asahiro, et al.
Publicado: (2021)

Giant cutaneous metastasis from hepatocellular carcinoma
por: Morishita, Asahiro, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients
por: Fujita, Koji, et al.
Publicado: (2018)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis
por: Fujita, Koji, et al.
Publicado: (2019)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021)

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve
por: Tomonari, Tetsu, et al.
Publicado: (2022)

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Galectin-9 ameliorates fulminant liver injury
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion
por: Nomura, Takako, et al.
Publicado: (2019)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
por: Oura, Kyoko, et al.
Publicado: (2021)

Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
por: Oura, Kyoko, et al.
Publicado: (2022)

Galectin-9 in Gastroenterological Cancer
por: Morishita, Asahiro, et al.
Publicado: (2023)

Cancer Therapy Due to Apoptosis: Galectin-9
por: Fujita, Koji, et al.
Publicado: (2017)

Nutritional Support for Alcoholic Liver Disease
por: Tadokoro, Tomoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hdaa89hdffv4f5jo9s807br1vu